Coronary Artery Disease Prognosis and C-reactive Protein Levels Improve in Proportion to Percent Lowering of Low-density Lipoprotein.
From: Mid America Heart Institute, Kansas City, Missouri, USA.
The American journal of cardiology
- Publish Date: Jul 2006
- ISSN: 0002-9149
- Volume: 98
- Issue: 1
- Pages: 135-9
- Medium: Print
- Language: English
- Citation (JAMA): O'Keefe James H, Cordain Loren, Jones Philip G, et al. Coronary Artery Disease Prognosis and C-reactive Protein Levels Improve in Proportion to Percent Lowering of Low-density Lipoprotein.. Am. J. Cardiol. Jul 2006;98:135-9
Abstract
This editorial outlines the data supporting aggressive lipid goals and options for treating low-density lipoprotein (LDL) cholesterol to a range of approximately 30 to 70 mg/dl. The physiologically normal cholesterol range is approximately 30 to 70 mg/dl for native hunter-gatherers, healthy human neonates, free-living primates, and virtually all wild mammals. Randomized statin trials in patients with recent acute coronary syndromes and stable coronary artery disease have demonstrated that cardiovascular events are reduced and cardiovascular survival optimized when LDL cholesterol is reduced to <70 mg/dl. Secondary prevention trials have shown a decrease in all-cause mortality in proportion to the magnitude of LDL cholesterol reduction. An original analysis of available data shows that the ability of a lipid-lowering therapy to reduce the C-reactive protein level is closely correlated with its efficacy in LDL cholesterol reduction. Randomized trial data have shown no relation between either percentage LDL cholesterol decrease or final LDL cholesterol level achieved and the risk for myopathy or hepatic transaminase elevations associated with statins. Therefore, intensive LDL cholesterol reduction to levels of 30 to 70 mg/dl should be pursued in subjects with or at high risk for coronary artery disease.
Mesh Headings (Keywords): Biological Markers, C-Reactive Protein, Cholesterol, LDL, Coronary Artery Disease, Humans, Inflammation, Prognosis, Randomized Controlled Trials as Topic, Risk Factors
Check for Full Text / PubMed Unique Identifier (PMID): 16784936
This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.
Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.
The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.